B.C. NDP leader Eby promises tax hike on wealthy to fund health care - Cranbrook Daily Townsman

Lindt hands out chocolate-filled briefcases to voting shareholders each year. From Patagonia vests to Rolex Submariners, the finance world is full of status symbols and fashion flexes. Wealthy Swiss investors have one of the weirdest: a blue briefcase filled with roughly 10 pounds of chocolate. Lindt shareholders who vote at the Swiss chocolatier's annual meeting in Zurich every April receive a "Schokoladekoffer" or "chocolate suitcase. "The briefcase is free, but a Lindt voting share costs around 78,000 Swiss francs, or more than $94,000. The shares have traded as high as 132,000 Swiss francs — north of $150,000 — within the past year. "Nobody rationally spends around 100,000 Swiss francs on a share because they want 3kg of free chocolate," Thierry Borgeat, the cofounder and chief investor of Swiss asset manager arvy, told Business Insider by email on Monday. "But that is exactly what makes it fun. ""It's a flex — but a very Swiss kind of flex," Borgeat continued. "You don't buy a Ferrari or a flashy watch to show people you have money.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.